Oncodesign Precision Medicine (XPAR:ALOPM) FFO


XPAR:ALOPM Oncodesign Precision Medicine SA XPAR:ALOPM
33 GF Score
Price €0.34
GF Value €0.29
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine FFO?

FFO (Funds from operations) only applies to REITs.

XPAR:ALOPM
33GF Score
Oncodesign Precision Medicine SA XPAR:ALOPM
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncodesign Precision Medicine (XPAR:ALOPM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.34 is trading 18.3% above its estimated GF Value™ of €0.29. GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.

Key valuation signals for XPAR:ALOPM:

  • FFO:
  • GF Value™: €0.29 vs. price of €0.34 (18.3% above fair value)
  • GF Score™: 33/100 with 1 warning sign

No single metric tells the full story. See the XPAR:ALOPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncodesign Precision Medicine Business Description

Other Exchanges ZR8:Germany
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
33GF Score

Get the complete analysis for XPAR:ALOPM

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price
€0.29
GF Value